Pelthos Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 19, 2026
PTHS$9.37+0.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Cash and cash equivalents | $17,973 | $513 |
| Restricted cash, current | 50 | — |
| Accounts receivable, net | 8,858 | — |
| Inventory, net | 23,574 | — |
| Prepaid expenses and other current assets | 2,955 | 856 |
| Total current assets | 53,410 | 1,369 |
| Property and equipment, net | 9,586 | — |
| Operating lease right-of-use assets, net | 3,250 | — |
| Intangible assets, net | 39,470 | — |
| Goodwill | 24,681 | — |
| Total assets | $130,397 | $1,369 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Accounts payable | $2,986 | $1,897 |
| Accrued expenses | 15,364 | — |
| Contingent consideration | 2,200 | — |
| Operating lease liabilities, current portion | 635 | — |
| Deferred revenue, current portion | 966 | — |
| Loan payable, net of debt discount | — | 2,054 |
| Loan payable - related party, net of debt discount | — | 132 |
| Other liabilities | 3,842 | — |
| Total current liabilities | 25,993 | 4,083 |
| Operating lease liabilities, net of current portion | 2,752 | — |
| Deferred revenue, net of current portion | 1,280 | — |
| Convertible debt | 31,441 | — |
| Other long-term liabilities | 30,050 | — |
| Total liabilities | 91,516 | 4,083 |
| Commitments and contingencies (Note 12) | ||
| STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Preferred stock Series A, $0.0001 par value, 150,000 shares authorized, 56,418 shares issued and outstanding as of December 31, 2025 and 700,000 shares authorized, no shares issued or outstanding as of December 31, 2024, respectively | — | — |
| Preferred stock Series C, $0.0001 par value, 5,000 shares authorized, 2,600 and 2,600 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized, 3,234,423 and 610,389 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | — | — |
| Additional paid in capital | 103,675 | 18,761 |
| Accumulated deficit | (64,794) | (21,475) |
| Total stockholders' equity (deficit) | 38,881 | (2,714) |
| Total liabilities and stockholders' equity (deficit) | $130,397 | $1,369 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.